Clinical Trial

Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2023 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder, and currently, manual repositioning techniques are often used for treatment. However, up to 30%-50% of patients may experience residual symptoms such as non-rotational dizziness, heaviness, instability, and emotional disturbances even after successful repositioning, which significantly impacts their daily functioning and quality of life. Electroacupuncture therapy has been proven to be an effective treatment for dizziness and has been applied to various vestibular disorder patients. However, the efficacy of electroacupuncture on the residual effects of successfully repositioned BPPV patients remains unclear. This study aims to explore the effectiveness of three regimens: electroacupuncture, betahistine in patients with residual symptoms after successful manual repositioning.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-13.
Status change: Not Yet Recruiting → Recruiting 2023-12-08
Trial Details
NCT Number NCT06001047
Lead Sponsor Xi'an No.3 Hospital
Conditions Benign Paroxysmal Positional Vertigo
Enrollment 120 participants
Start Date 2023-11-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-15